- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05048524
Peri-operative SLOG for Localized Pancreatic Cancer
Peri-operative S-1/Leucovorin, Oxaliplatin and Gemcitabine (SLOG) for Localized Pancreatic Cancer
- To evaluate the efficacy of neoadjuvant chemotherapy SLOG in localized pancreatic cancer
- To evaluate the safety profile in patients with pancreatic cancer who receive neoadjuvant SLOG
- To collect tumor tissue and peripheral blood samples from the patients for a comprehensive biomarker evaluation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan
- Recruiting
- Kaohsiung Medical University Hospital
-
Contact:
- Hui-Ching Wang, MD
- Phone Number: +8867-3121101
- Email: hcwang@kmu.edu.tw
-
Principal Investigator:
- Hui-Ching Wang
-
Tainan, Taiwan
- Recruiting
- National Cheng-Kung University Hospital
-
Contact:
- Yung-Yeh Su, MD
- Phone Number: 65181 +886-6-7000123
- Email: yysu@nhri.edu.tw
-
Principal Investigator:
- Li-Tzong Chen, MD, PhD
-
Tainan, Taiwan
- Recruiting
- National Institute of Cancer Research
-
Contact:
- Yung-Yeh Su, MD
- Phone Number: 65181 +8867-7000123
- Email: yysu@nhri.edu.tw
-
Principal Investigator:
- Li-Tzong Chen, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
A. Localized resectable or potentially resectable pancreatic cancer as determined by image modality; resectability is determined by the treating surgeon No prior treatment for pancreatic cancer
B. Patients must agree to receive biopsy for histological diagnosis and provide residual tissue for biomarker analysis before chemotherapy
C. Patients must agree to provide tissue for biomarker analysis after neoadjuvant chemotherapy, either surgical specimen or follow-up biopsy in unsectable disease
D. At least one measurable lesion according to RECIST version 1.1
E. Ability to understand and willingness to sign a written informed consent document.
F. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
G. Age of 20 years or above
H. Life expectancy of at least 12 weeks
I. Adequate organ function as defined by the following criteria:
- absolute neutrophil count (ANC) ≥ 1,500/mm3
- hemoglobin level ≥ 9 g/dL
- platelet count ≥ 100,000/mm3
- total bilirubin < 2 mg/dL
- aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN)
- creatinine clearance rate (CCr) ≥ 50 mL/min (24-hour urine collection or calculated by Cockroft-Gault formula; male: [(140 - age) × weight (kg)]/[72 × serum creatinine(mg/dL)];female=male x 0.85
J. Patients with childbearing potential shall have effective contraception for both the patient and his or her partner during the study.
Exclusion Criteria:
A. Other malignancy within the past 5 years except for adequately treated localized skin cancer or cervical cancer in situ;
B. Presence of distant metastasis;
C. Presence of mental disease or psychotic manifestation;
D. Active or uncontrolled infection;
E. Significant medical conditions that is contraindicated to study medication or render patient at high risk from treatment complications at physician discretion
F. Pregnant women or nursing mothers, or positive pregnancy test for women of childbearing potential.
G. History of active autoimmune disease within 3 years or use of steroid more than prednisolone 10mg/day.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SLOG
|
Gemcitabine 800 mg/m2 on day 1, oxaliplatin 85 mg/m2 on day 1, S-1 orally 80-120 mg/day [depending on patient's body surface area (BSA)] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The percentage of subjects with R0 resection after surgery
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 2 years
|
2 years
|
|
The percentage of subjects successfully underwent surgery after study drug treatment
Time Frame: 1 year
|
1 year
|
|
The percentage of subjects with tumor shrinkage >30%
Time Frame: 1 year
|
according to RECIST 1.1
|
1 year
|
The percentage of subjects without tumor progression
Time Frame: 1 year
|
tumor progression is defined as increase of size by >20% according to RECIST 1.1
|
1 year
|
Progression-free survival (PFS) of patient received study treatment
Time Frame: 1 year
|
1 year
|
|
Overall survival (OS) of patient received study treatment
Time Frame: 2 years
|
2 years
|
|
Duration of response (DOR) of patient received study treatment
Time Frame: 1 year
|
1 year
|
|
Biomarkers of treatment response by single cell RNA sequencing and whole exome sequencing
Time Frame: 4 years
|
Biomarkers including but not limited to tumor mutation burden, change of immune cell proportion and percentage of T-reg in the tumor microenvironment.
|
4 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Protective Agents
- Micronutrients
- Vitamins
- Antidotes
- Vitamin B Complex
- Oxaliplatin
- Leucovorin
- Gemcitabine
Other Study ID Numbers
- SLOG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Ductal Adenocarcinoma
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Georgetown UniversityERYtech PharmaActive, not recruitingMetastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Gilead SciencesTerminatedPreviously Untreated Pancreatic Ductal Adenocarcinoma | Relapsed/Refractory Pancreatic Ductal AdenocarcinomaUnited States
-
SOFIERecruitingFAP | PDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | Primary Pancreatic Ductal AdenocarcinomaUnited States
-
UMC UtrechtDutch Pancreatic Cancer Group (DPCG)Enrolling by invitationResectable Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Ductal AdenocarcinomaNetherlands
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers SquibbRecruitingPancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)United States
-
OHSU Knight Cancer InstituteGenentech, Inc.; Oregon Health and Science University; American Association for... and other collaboratorsRecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal AdenocarcinomaUnited States
-
Sohag UniversityCompletedPancreatic Adenocarcinoma
Clinical Trials on S-1, leucovorin, oxaliplatin and gemcitabine
-
Lin ChenUnknownGastric AdenocarcinomaChina
-
Peking University Cancer Hospital & InstituteRecruiting
-
Sun Yat-sen UniversityUnknown
-
Jilin Provincial Tumor HospitalUnknown
-
Fudan UniversityTerminated
-
Sixth Affiliated Hospital, Sun Yat-sen UniversitySun Yat-sen UniversityRecruitingChemotherapy Effect | Locally Advanced Gastroesophageal Junction AdenocarcinomaChina
-
Peking UniversityTaiho Pharmaceutical Co., Ltd.UnknownPancreatic Cancer | Biliary Tract Cancer | Periampullary AdenocarcinomaChina
-
Chinese PLA General HospitalUnknown
-
Chinese PLA General HospitalCure&Sure Biotech Co., LTDUnknownGastric CarcinomaChina
-
Shen Lin307 Hospital of PLA; Tianjin Medical University Cancer Institute and Hospital; Beijing Union Hosptial and other collaboratorsCompleted